BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE

VolverGo back

Resultados 40 results. LastUpdate Updated on 08/12/2021 [10:45:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Page1/2 nextPage   results/page


VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE

Publication No.: US2021371931A1 02/12/2021

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

KR_20210107176_A

Absstract of: US2021371931A1

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNF SF15 (or TL1A) and/or DcR3 genetic loci.

traducir

METHOD FOR BOWEL PREPARATION

Publication No.: US2021369847A1 02/12/2021

Applicant:

MSM INNOVATIONS INC [US]

JP_2020011982_A

Absstract of: US2021369847A1

The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.

traducir

METHOD AND KIT FOR DIAGNOSTING IRRITABLE BOWEL SYNDROME AND FOR ITS RELIEF THROUGH DIETARY INTERVENTIONS

Publication No.: EP3913371A1 24/11/2021

Applicant:

NEUROIMMUN GMBH [DE]

Absstract of: EP3913371A1

Method and kit for diagnosis of irritable bowel syndrome and irritable colon, comprising: a stool extraction system for preparation of a stool extract of substances of the gut-brain-axis, a derivatizing reagent for small biogenic amines; antibodies specific for derivatized tryptophan, serotonin, and GABA; and immunoassay reagents and buffers for combined determination of tryptophan, serotonin, and GABA. The method of in vitro diagnosis of irritable bowel syndrome (IBS) or irritable colon comprises a collecting a specimen of fresh stool; a transfer of the specimen into a stabilizing buffer; an extraction of the biogenic amines (neurotransmitters, neuroactive substances and tissue-active substances) and substances of the gut-brain axis; a combined quantitative analysis for tryptophan, serotonin and GABA, and optionally of histamine and kynurenic acid, to determine any imbalance of substances of the gut-brain-axis and for in vitro diagnosis of irritable bowel syndrome and/or irritable colon based on a comparison respective values and ranges in stools of healthy subjects.

traducir

DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES

Publication No.: EP3913364A1 24/11/2021

Applicant:

DYAX CORP [US]

ES_2873204_T3

Absstract of: EP3913364A1

Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

traducir

SECOND GENERATION SEQUENCING-BASED METHOD FOR DETECTING MICROSATELLITE STABILITY AND GENOME CHANGES BY MEANS OF PLASMA

Publication No.: US2021355544A1 18/11/2021

Applicant:

GUANGZHOU BURNING ROCK DX C LTD [CN]

BR_112021005966_A2

Absstract of: US2021355544A1

In one aspect, the present disclosure relates to a panel of biomarkers, a kit for detecting it, and its use in the detection of microsatellite instability (MSI) as well as non-invasive diagnosis, prognostic evaluation, selection of treatment or genetic screening of cancer, preferably colorectal cancer (such as bowel cancer), gastric cancer or endometrial cancer in a plasma sample. On the other hand, the present disclosure provides a method for detecting microsatellite instability (MSI) and disease-related gene mutations through plasma based on next-generation sequencing, and a device for implementing the method, especially the use of such detection method in the non-invasive diagnosis, prognostic evaluation, selection of treatment or genetic screening of patients with cancer, preferably colorectal cancer (such as bowel cancer), gastric cancer or endometrial cancer. This disclosure provides a plasma MSI detection method for the first time, which can determine the microsatellite instability of a sample with high accuracy and sensitivity.

traducir

USE OF MUCOSAL TRANSCRIPTOMES FOR ASSESSING SEVERITY OF ULCERATIVE COLITIS AND RESPONSIVENESS TO TREATMENT

Publication No.: US2021355538A1 18/11/2021

Applicant:

CHILDRENS HOSPITAL MED CT [US]

CA_3116005_PA

Absstract of: US2021355538A1

The present disclosure provides methods for assessing responsiveness or non-responsiveness to a therapeutic agent (e.g., steroid therapy, anti-TNF therapy or anti-integrin α4β7 therapy) in ulcerative colitis (UC) subjects based on gene signatures. The methods may further comprise identifying suitable treatment for the patient based on the gene signatures.

traducir

COMPOSITIONS AND METHODS FOR CHARACTERIZING BOWEL CANCER

Publication No.: WO2021224677A1 11/11/2021

Applicant:

AKERSHUS UNIV HF [NO]

Absstract of: WO2021224677A1

The present invention relates to compositions and methods for characterizing cancer. In particular, the present invention relates to compositions and methods for identifying bowel cancers at increased risk of metastasis.

traducir

COMPOSITIONS AND METHODS FOR PREVENTING, DETECTING, AND TREATING INFLAMMATORY BOWEL DISEASE

Publication No.: WO2021222806A1 04/11/2021

Applicant:

ICAHN SCHOOL MED MOUNT SINAI [US]
GOVERNING COUNCIL UNIV TORONTO [CA]

Absstract of: WO2021222806A1

The present disclosure relates to a composition comprising a post-translationally modified Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) protein. The disclosure further relates to methods of preventing or treating Crohn's Disease and/or a condition resulting from Crohn's Disease in a subject. The disclosure further relates to methods for diagnosing and/or predicting severity of and/or treating Crohn's Disease in a subject. Also disclosed are methods for diagnosing inflammatory bowel disease in a subject and methods for diagnosing a pre-disease state of Crohn's Disease in a subject.

traducir

Methods of diagnosing disease

Publication No.: AU2020255035A1 28/10/2021

Applicant:

4D PHARMA CORK LTD [IE]

AU_2020255277_A1

Absstract of: AU2020255035A1

The application provides new and improved methods for diagnosing IBS.

traducir

DYSREGULATION OF COVID-19 RECEPTOR ASSOCIATED WITH IBD

Publication No.: US2021332122A1 28/10/2021

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

Absstract of: US2021332122A1

Provided herein are methods, systems and kits for use in identifying a subject with an increased risk of developing severe forms of inflammatory bowel disease (IBD), based at least in part, on an expression of one or more biomarkers detected in a biological sample obtained from the subject. Also provided are methods, systems and kits for treating, or optimizing the treatment for, the IBD based, at least in part, on the expression the one or more biomarkers. In some embodiments, the one or more biomarkers is angiotensin-converting enzyme 2 (ACE2), the host receptor for severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2).

traducir

CELL ATLAS OF THE HEALTHY AND ULCERATIVE COLITIS HUMAN COLON

Publication No.: US2021325387A1 21/10/2021

Applicant:

BROAD INST INC [US]
MASSACHUSETTS INST TECHNOLOGY [US]
MASSACHUSETTS GEN HOSPITAL [US]

WO_2019018440_PA

Absstract of: US2021325387A1

The present invention provides for a human cell atlas of the colon from healthy and diseased subjects. The atlas was obtained by single sequencing of about 117,000 cells. The present invention discloses novel markers for cell types. Moreover, genes associated with disease are identified in the colon and colon specific cell types. The invention provides for diagnostic assays based on gene markers and cell composition, as well as target cell types that express genes associated with disease. Finally, disclosed are novel cell types and methods of quantitating, detecting and isolating the cell types.

traducir

METHODS AND DEVICES FOR DETECTING BOWEL PERFORATION

Publication No.: US2021321936A1 21/10/2021

Applicant:

SENTIRE MEDICAL SYSTEMS INC [US]

US_2019053749_A1

Absstract of: US2021321936A1

The present disclosure relates to methods and devices to detect perforation of the bowel, for example, resulting from surgical procedures, such as laparoscopy, diagnostic procedures, such as colonoscopy, medical conditions, such as diverticulitis, and trauma. The present disclosure also relates to filtration systems and electrical connector assemblies for use in the methods and devices.

traducir

Methods and Treatment Involving Excess Free Light

Publication No.: US2021324066A1 21/10/2021

Applicant:

AEVI GENOMIC MEDICINE LLC [US]

WO_2021202649_A2

Absstract of: US2021324066A1

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

traducir

LIPOCALIN-2 ASSAY FOR INTESTINAL ADAPTATION

Publication No.: WO2021207725A1 14/10/2021

Applicant:

UNIV JOHNS HOPKINS [US]

Absstract of: WO2021207725A1

The present invention relates to the field of short bowel syndrome. More specifically, the present invention provides methods and compositions useful for assaying for intestinal adaptation. In a specific embodiment, a method for treating a patient having SBS who is undergoing parenteral nutrition comprises the steps of (a) measuring lipocalin-2 (LCN2) in a sample obtained from the patient; and (b) reducing or eliminating parenteral nutrition if the measured level of LCN2 is below a control level or treating the patient with IL-22, a LCN2 inhibitor and/or an AHR agonist if the measured level of LCN2 is above the control level.

traducir

METHODS AND TREATMENT INVOLVING EXCESS FREE LIGHT

Publication No.: WO2021202649A2 07/10/2021

Applicant:

AEVI GENOMIC MEDICINE LLC [US]

US_2021324066_A1

Absstract of: WO2021202649A2

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

traducir

MICROBIOME-BASED THERAPEUTICS

Publication No.: WO2021195636A1 30/09/2021

Applicant:

UNIV CORNELL [US]

Absstract of: WO2021195636A1

Provided herein is a method of treating an individual afflicted with an inflammatory bowel disease utilizing Candida abundance as a biomarker of responsiveness. The method comprises determining levels of Candida in a sample from the gastrointestinal tract of an individual, and if the level of Candida is higher than a reference level, identifying the individual as suitable for microbiota transplantation therapy (MTT), and optionally, administering to such an individual the MTT, and in individuals having gastrointestinal tract Candida levels lower than a reference level, increasing the Candida levels prior to prior to administration of MTT.

traducir

PREDICTING A TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE

Publication No.: EP3884276A2 29/09/2021

Applicant:

UNIV LEUVEN KATH [BE]

WO_2020104705_A2

Absstract of: WO2020104705A2

In general the present invention concerns a method for predicting the therapeutic outcome of a treatment of in inflammatory bowel disease for anti-TNF agents, anti- α4β7-intcgrin agents and/or anti- IL-12/23 agents. The method defines which the agents are likely to provide the best healing effect for a particular patients affected by an inflammatory bowel disease. In particular the method predicts the therapeutic outcome of a treatment of anti-TNF agents in inflammatory bowel disease.

traducir

METHODS AND COMPOSITIONS FOR PREDICTION OF RESPONSE TO A THERAPY OF AN INFLAMMATORY BOWEL DISEASE

Publication No.: EP3880836A1 22/09/2021

Applicant:

JANSSEN BIOTECH INC [US]

EA_202191354_A1

Absstract of: WO2020102519A1

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

traducir

TARGETED HD5 ANTIBODY AND ASSAY METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

Publication No.: US2021278417A1 09/09/2021

Applicant:

MEHARRY MEDICAL COLLEGE [US]

CN_111032053_A

Absstract of: US2021278417A1

A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohns disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohns disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohns disease.

traducir

VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE

Publication No.: KR20210107176A 31/08/2021

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

US_2021371931_A1

Absstract of: WO2014186750A2

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.

traducir

METHODS AND COMPOSITIONS FOR PREDICTION OF RESPONSE TO THERAPY OF INFLAMMATORY BOWEL DISEASE

Publication No.: CN113316647A 27/08/2021

Applicant:

JANSSEN BIOTECH INC

EA_202191354_A1

Absstract of: CN113316647A

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

traducir

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE

Publication No.: US2021261651A1 26/08/2021

Applicant:

ARTIZAN BIOSCIENCES [US]

JP_2021529828_A

Absstract of: US2021261651A1

Described are compositions and methods for treating inflammatory bowel diseases in a subject in need thereof. In certain aspects, the disclosure provides methods of treating a subject diagnosed with Irritable Bowel Disease (IBD), the method comprising administering to the subject an agent to reduce the number or pathogenic effects of a B. fragilis strain, wherein the subject is diagnosed with IBD by detecting the presence of the B. fragilis strain or a B. fragilis toxin in a biological sample of the patient.

traducir

USE OF MUCOSAL TRANSCRIPTOMES FOR ASSESSING SEVERITY OF ULCERATIVE COLITIS AND RESPONSIVENESS TO TREATMENT

Publication No.: EP3867399A1 25/08/2021

Applicant:

CHILDRENS HOSPITAL MED CT [US]

US_2021355538_A1

Absstract of: WO2020082011A1

The present disclosure provides methods for assessing responsiveness or non- responsiveness to a therapeutic agent (e.g., steroid therapy, anti-TNF therapy or anti-integrin α4β7 therapy) in ulcerative colitis (UC) subjects based on gene signatures. The methods may further comprise identifying suitable treatment for the patient based on the gene signatures.

traducir

METHODS OF TREATING AND DIAGNOSING INFLAMMATORY BOWEL DISEASE

Publication No.: EP3866793A1 25/08/2021

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

WO_2020081186_PA

Absstract of: WO2020081186A1

Described herein are methods of treatment of an inflammatory condition related to fungal immunity. The present disclosure relates to methods and systems for identifying patients suitable for treatment with active agents, as described herein. Further, described herein are various compositions for treating and identifying a subject in need of an active agent for treatment.

traducir

SYSTEMS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE THROUGH PERIPHERAL NERVE STIMULATION

Nº publicación: US2021252278A1 19/08/2021

Applicant:

CALA HEALTH INC [US]

WO_2019143790_PA

Absstract of: US2021252278A1

Systems and methods for treating symptoms of an inflammatory gastrointestinal disease in a patient with transcutaneous stimulation of a peripheral nerve are disclosed. The method can include any number of positioning a first peripheral nerve effector on the patient's skin to stimulate the peripheral nerve of the patient, delivering a first electrical nerve stimulation signal transcutaneously to the peripheral nerve through the first peripheral nerve effector, and modifying at least one brain or spinal cord autonomic feedback loop relating to release of neurotransmitters from the autonomic nervous system that modulate synthesis of inflammatory biomarkers and reduce inflammation relating to the inflammatory gastrointestinal disease.

traducir

Page1/2 nextPage results/page

punteroimgGo back